Nicolás Federico: Aldosterone Dysregulation as a Driver of Cardiorenal Disease
Nicolás Federico, Fellow of the International Society of Hypertension, Adjunct Professor of Medicine at the National University of Cuyo, and Head of the Hypertension Unit at Hospital Español de Mendoza, shared a post on LinkedIn։
՛՛Aldosterone dysregulation as a driver of cardiorenal disease
A recent narrative review published in Current Heart Failure Reports (Erzeel et al., 2026) revisits the evolution of mineralocorticoid pathway modulation across heart failure and chronic kidney disease, shifting the focus from drugs to pathophysiology.
Rather than viewing aldosterone merely as a volume-regulating hormone, growing evidence supports its role in a broader maladaptive phenotype characterized by:
- sodium retention and volume expansion
- vascular inflammation and fibrosis
- cardiac remodeling and hypertrophy
- renal injury and albuminuria
- sympathetic overactivation
From a mechanistic perspective, different therapeutic strategies act at distinct levels of the aldosterone pathway:
Mineralocorticoid receptor antagonists (steroidal and non-steroidal) primarily block downstream tissue effects.
Emerging aldosterone synthase inhibitors aim to suppress upstream aldosterone production, potentially preventing hormonal breakthrough.
This framework highlights an important concept:
aldosterone dysregulation may define different cardiorenal phenotypes, each requiring a tailored therapeutic approach.
Importantly, this pathophysiological view may also help interpret heterogeneity in treatment response across hypertension, heart failure, and chronic kidney disease populations.
As outcome trials continue to mature, understanding where and how we intervene along this pathway will be central to precision cardiorenal medicine.՛՛
Stay updated with Hemostasis Today.
-
Jul 13, 2026, 18:54Alfonso J. Tafur: New Evidence on Perioperative Anticoagulation in Cancer at ISTH 2026
-
Jul 13, 2026, 18:42Jessica Garcia: Thrombin Generation in Type 3 VWD With an Inhibitor on Emicizumab
-
Jul 13, 2026, 18:19Fionnuala Ní Áinle: High-Quality Evidence for DVT Diagnosis in Pregnancy at ISTH 2026
-
Jul 13, 2026, 17:39Pascal Boulanger: Send a Postcard to Your Lab Staff From ISTH 2026
-
Jul 13, 2026, 17:21Stefano Navarro: Presenting Our Recently Published Article at ISTH 2026
-
Jul 13, 2026, 17:12Santagata Davide: A Great Session and an Incredible Opportunity to Present Our Research at ISTH 2026
-
Jul 13, 2026, 16:26Real-World Data Across Time Reveal Important Advances in Hemophilia Treatment – ATHN
-
Jul 13, 2026, 16:19Mary Cushman: Celebrating Our Incredible ISTH Council Members in Paris
-
Jul 13, 2026, 16:17Wolfgang Miesbach: Gene Therapy Shows Promising Early Results in Adolescents With Hemophilia B at ISTH 2026